Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer

References

• Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg.210(4), 474–484; discussion 484–475 (1989).
   PubMed Web of Science ®Google Scholar
• Holdener EE, Emmons RP, Brunda M, Evans L, Levitt D. Interferon-α and interleukin-2 in the treatment of renal cell cancer. Prog. Clin. Biol. Res.348, 61–69 (1990).
   PubMedGoogle Scholar
• Ressing ME, Offringa R, Toes RE et al. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology2(4), 241–251 (1996).
   PubMedGoogle Scholar
• Chakraborty NG, Stevens RL, Mehrotra S et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol. Immunother.52(8), 497–505 (2003).
   PubMed Web of Science ®Google Scholar
• Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics – theory. Urology17(Suppl. 3), 40–53 (1981).
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res.62(15), 4427–4433 (2002).
   PubMed Web of Science ®Google Scholar
• Fong L, Small EJ. Immunotherapy for prostate cancer. Semin. Oncol.30(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Cereda V, Poole DJ, Palena C et al. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother.59(1), 63–71 (2010).
   PubMed Web of Science ®Google Scholar
• Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol.145(5), 907–923 (1991).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A et al. Combining a recombinant cancer vaccine with standard deflnitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res.11(9), 3353–3362 (2005).
   PubMed Web of Science ®Google Scholar
• Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. lmmunol.24(5), 571–578 (2000).
   Google Scholar
• Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res.6(6), 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev. Anticancer Ther.6(9), 1163–1167 (2006).
   PubMed Web of Science ®Google Scholar
• Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature362(6422), 755–758 (1993).
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA294(2), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol.18(23), 3894–3903 (2000).
   PubMed Web of Science ®Google Scholar
• Burch PA, Croghan GA, Gastineau DA et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate60(3), 197–204 (2004).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Small E, Rini B, Higano C et al. A randomized, placebo-controlled Phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa) [abstract]. Proc. Am. Soc. Clin. Oncol.22, 1534 (2003).
   Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Sheikh N, Jones L. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol. Immunother.57(9), 1381–1390 (2008).
   PubMed Web of Science ®Google Scholar
• Stewart F, dela Rosa C, Sheikh N et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer [abstract]. J. Clin. Oncol.28(15S), 4552 (2010).
   Google Scholar
• Frohlich M, Sheikh N, Xu Y, Whitmore J, Poehlein C, Urdal D. Sipuleucel-T immune parameters and correlation with overall survival. Presented at: iSBTC 25th Annual Scientific Meeting. Washington, DC, USA, 30 September–4 October 2010.
   Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Osoba D, Murphy K et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol.12(4), 689–694 (1994).
   PubMed Web of Science ®Google Scholar
• Kelly W, Halabi S, Carducci M et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract]. J. Clin. Oncol.28(18s), LBA4511 (2010).
   Web of Science ®Google Scholar
• Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res.12(2), 134–141 (1952).
   PubMed Web of Science ®Google Scholar
• Furr BJ. “Casodex” (ICI 176,334) – a new, pure, peripherally-selective anti-androgen: preclinical studies. Horm. Res.32(Suppl. 1), 69–76 (1989).
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs9(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.26(28), 4563–4571 (2008).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.27(23), 3742–3748 (2009).
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.28(9), 1496–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375(9724), 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Sartor A, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational Phase III trial (TROPIC). Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010.
   Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol.26(15), 2544–2549 (2008).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother.59(5), 663–674 (2010).
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 479–481 (2010).
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs18(7), 1001–1011 (2009).
   PubMed Web of Science ®Google Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther.4(4), 575–588 (2004).
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate53(2), 109–117 (2002).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.22(11), 2122–2132 (2004).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol.178(4 Pt 1), 1515–1520 (2007).
   PubMed Web of Science ®Google Scholar
• DiPaola R, Chen Y, Bubley G et al. A Phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: Results of ECOG 9802. Presented at: ASCO Genitourinary Cancers Symposium. Orlando, FL, USA, 26–28 February 2009.
   Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res.59(22), 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res.62(20), 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res.61(11), 4497–4505 (2001).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Baghdadi R. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product. Oncology24(10), 881–883 (2010).
   PubMed Web of Science ®Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101(15), 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Cancer patients receiving chemotherapy: opportunities for better management. Milliman Client Report. Milliman Inc., NY, USA, 1–30 (2010).
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist15(9), 969–975 (2010).
   PubMed Web of Science ®Google Scholar
• Stein WD, Gulley J, Schlom J et al.Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin. Cancer Res. DOI: 10.1158/1078-0432.CCR-10-1762 (2010) (Epub ahead of print).
   Google Scholar
• Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol.26(7), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin. Biol. Ther.10(1), 19–28 (2010).
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol.27(25), 4047–4054 (2009).
   PubMed Web of Science ®Google Scholar
• Zlotocha S, Staab MJ, Horvath D et al. A Phase I study of a DNA vaccine targeting prostatic acid phosphatase in patients with stage D0 prostate cancer. Clin. Genitourin. Cancer4(3), 215–218 (2005).
   PubMedGoogle Scholar
• Arlen PM, Gulley JL, Todd N et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol.174(2), 539–546 (2005).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res.11(9), 3353–3362 (2005).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res.12(4), 1260–1269 (2006).
   PubMed Web of Science ®Google Scholar
• Tseng CW, Trimble C, Zeng Q et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol. Immunother.58(5), 737–748 (2009).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Demaria S, Lukyanov Y et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res.12(15), 4730–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res.64(21), 7985–7994 (2004).
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res.14(14), 4526–4531 (2008).
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA98(25), 14565–14570 (2001).
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci.12, 4957–4971 (2007).
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell7(3), 239–249 (2005).
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science270(5238), 985–988 (1995).
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol.3(7), 611–618 (2002).
   PubMed Web of Science ®Google Scholar
• Allison JP, Chambers C, Hurwitz A et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found. Symp.215, 92–98; discussion 98–102, 186–190 (1998).
   PubMedGoogle Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J. Immunol.174(10), 5994–6004 (2005).
   PubMed Web of Science ®Google Scholar
• Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol. Immunother.59(3), 397–408 (2010).
   PubMed Web of Science ®Google Scholar